Anzeige
Mehr »
Dienstag, 17.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A41BJC | ISIN: KYG144922047 | Ticker-Symbol:
NASDAQ
13.02.26 | 21:49
1,640 US-Dollar
0,00 % 0,000
Branche
Gesundheitswesen
Aktienmarkt
ASIEN
1-Jahres-Chart
BON NATURAL LIFE LIMITED Chart 1 Jahr
5-Tage-Chart
BON NATURAL LIFE LIMITED 5-Tage-Chart
PR Newswire
157 Leser
Artikel bewerten:
(1)

Bon Natural Life Limited: BON Announced Next-Gen of Tea Pigment Digestive Health Products and Cooperation Agreement of US$26 Million with Beijing Huahai Keyuan

XI'AN, China, Nov. 25, 2025 /PRNewswire/ -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), a leading bio-ingredient solution provider in the natural, health and personal care industry, today announ ced a non-e xclusive cooperation agreement with Beijing Huahai Keyuan Technology Co. Ltd. ("Huahai Keyuan") a prominent health products distributor in China. The term of the agreement is 36 months with a total contract value of US$26 million. Pursuant to the agreement, Huahai Keyuan will sell and distribute BON's second-generation tea pigment-based digestive health products in Greater China.

Tea pigments, a key bioactive complex derived from tea, possess a strong scientific profile across lipid regulation, glycemic control, antioxidant function, and gastrointestinal support. As a next-generation functional tea ingredient, tea pigments represent the most significant innovation in the sector since the commercialization of tea polyphenols. Current market adoption is being driven primarily by two fast-growing segments: digestive wellness and blood-glucose management. With broad applicability and favorable consumer demand trends, tea pigments are positioned as a potential blockbuster ingredient with an anticipated market opportunity exceeding US$1 billion in the coming years.

As a global leading innovator in tea pigment ingredients, BON has identified that targeted biotransformation of tea raw materials can significantly enhance the functional performance of tea pigments. Leveraging this, BON undertook systematic research utilizing its proprietary, optimally selected Eurotium cristatum strain as a fermentation agent. Through a controlled biotransformation process - a precision-optimized fermentation method designed to strengthen functional attributes - BON believes it has achieved a substantial improvement in the digestive health benefits of tea pigments.

Testing demonstrates that the digestive health activity of BON's latest tea pigment product has increased by more than 200% compared to first-generation formulations, representing a major advancement in product efficacy and competitive positioning.

Hu Yongwei, CEO and Chairman of BON, stated: "Through our strategic partnership with Huahai Keyuan, BON will leverage its competitive strengths and continued innovation in tea pigment technology to accelerate our expansion into the rapidly growing premium digestive health market. This agreement marks the next phase of BON's strategic development and positions us to drive synergistic growth across the digestive health sector. We also plan to introduce our innovative second-generation tea pigment product portfolio to global markets. BON believes this partnership will support meaningful revenue and earnings growth over time and further enhance long-term shareholder value."

About Bon Natural Life Limited ("BON")

BON is a Cayman Islands company engaged in the business of natural, health, and personal care industries. For more information, please visit the Company's website at http://www.bnlus.com.

For more information, please contact:

Cindy Liu | IR
Email: [email protected]

Safe Harbor Statement

This press release contains certain statements that may include "forward-looking statements." All statements other than statements of historical fact included herein are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "believes,""expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

SOURCE Bon Natural Life Limited

© 2025 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.